Fiscal Year 2026 Expectations
Filed Oct 21, 2026Cencora to acquire American Oncology Network and raises fiscal year 2026 adjusted diluted EPS expectation to at least $17.90.
Cencora raised its fiscal year 2026 adjusted diluted EPS expectation to at least $17.90, citing strength in U.S. Healthcare Solutions, while announcing an oncology-network acquisition expected to be accretive to adjusted diluted EPS in the second year post-closing.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Fiscal Year 2026 adjusted diluted earnings per share expectationnon-GAAP | at least $17.90 | – | – |
| American Oncology Network transaction enterprise valueother | $2.4B | – | – |
| American Oncology Network transaction value at closingother | $2.3B | – | – |
| American Oncology Network contingent value rightsother | up to $100 million | – | – |
| Expected cash payment assuming 25% equity rolloverother | approximately $1.7 billion | – | – |
| Cencora current ownership of American Oncology Networkother | approximately 4% | – | – |
| Potential American Oncology Network equity rolloverother | up to 25% | – | – |
| Expected Cencora ownership of American Oncology Network assuming 25% equity rolloverother | 75% | – | – |
Fiscal Year 2026 outlook
- NoteAdjusted diluted earnings per share (EPS) of at least $17.90
- NotePrevious range of $17.75 to $17.95
- NoteThe acquisition is expected to be accretive to Cencora’s adjusted diluted EPS in the second year post-closing.
What drove it
- Cencora updated fiscal year 2026 financial guidance to reflect the strength of the U.S. Healthcare Solutions reportable segment.
- The acquisition is intended to expand Cencora’s physician-led oncology MSO and add complementary capabilities.
- AON has more than 350 oncology providers across 21 states.
- Cencora stated that the transaction would expand its presence across twelve additional states.
- Cencora expects the acquisition to be accretive to adjusted diluted EPS in the second year post-closing.
Concerns
- The transaction remains subject to customary closing conditions, including required regulatory clearances and AON stockholder approvals.
- Cencora identified risks around realizing expected benefits, synergies and operating efficiencies, and promptly and effectively integrating AON.
- Cencora identified the possibility that the transaction could be more expensive to complete than anticipated.
- Cencora identified its de-leveraging plans and ability to maintain its investment grade rating as transaction-related risk considerations.
- Cencora does not provide forward-looking guidance on a GAAP basis.
What to watch
- Cencora’s fiscal fourth quarter 2026 earnings call on November 4, 2026, when it expects to discuss fiscal 2027 expectations.
- Progress toward regulatory clearances and AON stockholder approval.
- The ultimate equity rollover participation by certain AON stockholders.
- The timing of closing and the acquisition’s path to adjusted diluted EPS accretion in the second year post-closing.
- Continued strength in the U.S. Healthcare Solutions reportable segment.
Balance sheet and cash flow
- Cencora expects to pay approximately $1.7 billion to increase its ownership in AON to 75%, assuming certain AON stockholders retain 25% of AON through the equity rollover.
- The transaction values AON at an enterprise value of $2.4 billion, consisting of $2.3 billion at closing and contingent value rights of up to $100 million.
Analysis
This filing is an acquisition and guidance update rather than a quarterly earnings release. Cencora raised its fiscal year 2026 adjusted diluted EPS expectation to at least $17.90, described as the high end of its previous range of $17.75 to $17.95. Management attributed the update to strength in the U.S. Healthcare Solutions reportable segment. The company does not provide forward-looking GAAP guidance.
The proposed acquisition of American Oncology Network expands Cencora’s oncology MSO strategy. AON is described as a physician-led network of more than 350 oncology providers across 21 states, while Cencora says the transaction expands its presence across twelve additional states. The stated strategic rationale centers on enhanced support capabilities for independent practices, technology and practice support, and broader access to community-based oncology care.
The transaction values AON at an enterprise value of $2.4 billion, comprising $2.3 billion at closing and contingent value rights of up to $100 million. Cencora already owns approximately 4% of AON. If certain AON stockholders retain 25% of AON through an equity rollover, Cencora expects to pay approximately $1.7 billion to increase its ownership to 75%.
Management expects the acquisition to be accretive to adjusted diluted EPS in the second year post-closing, making execution and integration central to the financial case. The filing identifies closing approvals, integration, expected synergies, transaction costs, de-leveraging and maintenance of Cencora’s investment grade rating as relevant risks. No revenue, margin, earnings, cash flow, balance sheet, or capital-return results for a completed reporting period were included.
The next disclosed financial milestone is Cencora’s fiscal fourth quarter 2026 earnings call on November 4, 2026, when management expects to discuss fiscal 2027 expectations. Investors will need to monitor transaction approvals, rollover participation, closing timing, and whether the strength cited in U.S. Healthcare Solutions continues into fiscal 2027.
Management, verbatim
The acquisition of AON will expand our physician-led oncology MSO and support of care in communities across the country.
Robert P. Mauch, President and Chief Executive Officer of Cencora
This is the next chapter of the same mission: high-quality, accessible cancer care delivered close to home, led by physicians who know their patients best.
Todd Schonherz, Chief Executive Officer of American Oncology Network
Not in the filing
stated, not guessed- Period end date
- Reported actual revenue
- Reported revenue by segment
- GAAP gross margin
- Non-GAAP gross margin
- GAAP operating income
- Non-GAAP operating income
- GAAP net income
- Non-GAAP net income
- GAAP diluted earnings per share
- Reported actual non-GAAP adjusted diluted earnings per share
- Operating cash flow
- Free cash flow
- Cash balance
- Debt balance
- Share repurchases
- Dividend amount
- Revenue guidance
- Gross margin guidance
- Operating expense guidance
- Tax-rate guidance
- Prior fiscal year or prior quarter comparisons for reported operating metrics
- Previous outlook section for a prior-guidance comparison
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.